Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 523

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer

Open access
Xing, Mingzhao, Alzahrani, Ali S., Carson, Kathryn A., Shong, Young Kee, Kim, Tae Yong, Viola, David, Elisei, Rossella, Bendlová, Bela, Yip, Linwah, Mian, Caterina, Vianello, Federica, Tuttle, R. Michael, Robenshtok, Eyal, Fagin, James A., Puxeddu, Efisio, Fugazzola, Laura, Czarniecka, Agnieszka, Jarzab, Barbara, O'Neill, Christine J., Sywak, Mark S., Lam, Alfred K., Riesco-Eizaguirre, Garcilaso, Santisteban, Pilar, Nakayama, Hirotaka, Clifton-Bligh, Roderick, Tallini, Giovanni, Holt, Elizabeth H., Sýkorová, Vlasta·2015·Journal of Clinical Oncology

Abstract

Purpose: To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillary thyroid cancer (PTC). Patients and Methods: This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months). Results: The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAF V600E mutation–positive and 11.6% (125 of 1,082) of BRAF V600E mutation–negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation–positive versus –negative patients (P < .001), with a hazard ratio (HR) of 1.82 (95% CI, 1.46 to 2.28), which remained significant in a multivariable model adjusting for patient sex and age at diagnosis, medical center, and various conventional pathologic factors. Significant association between BRAF mutation and PTC recurrence was also found in patients with conventionally low-risk disease stage I or II and micro-PTC and within various subtypes of PTC. For example, in BRAF mutation–positive versus –negative follicular-variant PTC, recurrence occurred in 21.3% (19 of 89) and 7.0% (24 of 342) of patients, respectively, with recurrence rates of 53.84 (95% CI, 34.34 to 84.40) versus 19.47 (95% CI, 13.05 to 29.04) per 1,000 person-years (P < .001) and an HR of 3.20 (95% CI, 1.46 to 7.02) after adjustment for clinicopathologic factors. BRAF mutation was associated with poorer recurrence-free probability in Kaplan-Meier survival analyses in various clinicopathologic categories. Conclusion: This large multicenter study demonstrates an independent prognostic value of BRAF V600E mutation for PTC recurrence in various clinicopathologic categories.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.56.8253

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 523

Metadata

Authors
Xing, M., Alzahrani, A. S., Carson, K. A., Shong, Y. K., Kim, T. Y., Viola, D., Elisei, R., Bendlová, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., Robenshtok, E., Fagin, J. A., Puxeddu, E., Fugazzola, L., Czarniecka, A., Jarzab, B., O'Neill, C. J., Sywak, M. S., Lam, A. K., Riesco-Eizaguirre, G., Santisteban, P., Nakayama, H., Clifton-Bligh, R., Tallini, G., Holt, E. H., & Sýkorová, V.
Venue
Journal of Clinical Oncology
Published
2015-01-01
Volume
33
Issue
1
Pages
42-50
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2130662884
Cited by
523
References
3
FWCI
38.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. https://app.cochat.ai/papers/10.1200/jco.2014.56.8253
The paper
Xing, M., Alzahrani, A. S., Carson, K. A., Shong, Y. K., Kim, T. Y., Viola, D., Elisei, R., Bendlová, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., Robenshtok, E., Fagin, J. A., Puxeddu, E., Fugazzola, L., Czarniecka, A., Jarzab, B., O'Neill, C. J., . . . Sýkorová, V. (2015). Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.56.8253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.